Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shukra PharmaceuticalsBOM:524632 -1.66%67 Days Payable is 154.61 as of Mar. 2026, which is 50% below its 10-year median of 307.68. GuruFocus rates BOM:524632 with a GF Score™ of 67/100 and a GF Value™ of ₹8.66 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 927 Drug Manufacturers companies, Shukra Pharmaceuticals ranks better than 85.98% on this metric.
The historical rank and industry rank for Shukra Pharmaceuticals's Days Payable or its related term are showing as below:
BOM:524632'
s Days Payable Range Over the Past 10 Years
Min: 167.55 Med: 307.68 Max: 752.46
Current: 211.53
During the past 13 years, Shukra Pharmaceuticals's highest Days Payable was 752.46. The lowest was 167.55. And the median was 307.68.
BOM:524632's Days Payable is ranked better than 85.98% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:524632: 211.53
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Shukra Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shukra Pharmaceuticals Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shukra Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Shukra Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Shukra Pharmaceuticals's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shukra Pharmaceuticals (BOM:524632) has a Days Payable of 154.61 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shukra Pharmaceuticals and its competitors. This is 50% below median its historical median of 307.68. Over the past decade, Shukra Pharmaceuticals' Days Payable has ranged from 167.55 to 752.46. According to the industry distribution chart, Shukra Pharmaceuticals ranks #130 out of 927 companies in the Drug Manufacturers industry, placing it in the top 14%.
Is Shukra Pharmaceuticals' Days Payable too high?
Shukra Pharmaceuticals' current Days Payable of 154.61 is 50% below median its 10-year median of 307.68. Over the past 10 years, this metric has ranged from a low of 167.55 to a high of 752.46. The Drug Manufacturers industry median Days Payable is 90.38. Shukra Pharmaceuticals' value of 154.61 is 71.1% above this industry median. Based on the distribution chart, Shukra Pharmaceuticals ranks #130 out of 927 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Shukra Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shukra Pharmaceuticals' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Shukra Pharmaceuticals ranks #130 out of 927 companies for Days Payable. This places Shukra Pharmaceuticals in the top 14% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.38. Shukra Pharmaceuticals' value of 154.61 is 71.1% above this benchmark. Historically, Shukra Pharmaceuticals' own Days Payable has ranged from 167.55 to 752.46 over the past decade. While the company's 10-year median is 307.68 vs. the industry median of 90.38, Shukra Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shukra Pharmaceuticals's current Days Payable of 154.61 is 71.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Shukra Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shukra Pharmaceuticals's current Days Payable is 154.61, which is 50% below median its own 10-year median of 307.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shukra Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Shukra Pharmaceuticals (BOM:524632) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹8.66, compared to a current price of ₹33.13 — trading 282.6% above its estimated fair value. The current Days Payable is 154.61, which is 50% below median its 10-year median of 307.68 and 71.1% above the Drug Manufacturers industry median of 90.38. Shukra Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Shukra Pharmaceuticals (BOM:524632), the current Days Payable is 154.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shukra Pharmaceuticals (BOM:524632) Overvalued in 2026?
Based on GuruFocus' analysis, Shukra Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹33.13 is trading 282.6% above its estimated GF Value™ of ₹8.66.
GuruFocus considers Shukra Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:524632:
Days Payable: 154.61 (50% below median its 10-year median of 307.68)
GF Value™: ₹8.66 vs. price of ₹33.13 (282.6% above fair value)
Industry Position: 71.1% above the Drug Manufacturers median (#130 of 927)
No single metric tells the full story. See the BOM:524632 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shukra Pharmaceuticals Ltd is engaged in the business of manufacturing and trading pharmaceutical products. The company markets its products in India and international markets. The company has two operating segments: Pharmaceutical and Laboratory. Its product portfolio includes antibiotics, quinolones, macrolides, antibacterials, antifungals, antimalarials, antivirals, antiprotozoals, anthelmintics, antidepressants, antimanics, antiemetics, beta-blockers, analgesics, muscle relaxants, antituberculosis agents, vitamin products, antiallergics, corticosteroids, hyperglycemic and hypoglycemic agents, and others. It exports its products to Australia, Uganda, Kenya, the United Kingdom, Sri Lanka, Mauritius, and the Republic of Yemen.
67GF Score
Get the complete analysis for BOM:524632
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524632 has been successfully added to your 
